Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors

Andrew James Wardle, Robert M R Tulloh

Research output: Contribution to journalArticle (Academic Journal)

8 Citations (Scopus)

Abstract

The treatment of pulmonary arterial hypertension (PAH) has undergone significant change in recent years, improving both quality of life and survival for patients. One of the principal new agents is sildenafil, a phosphodiesterase-V inhibitor with great PAH efficacy. Its success has led to consideration of other phosphodiesterase inhibitors not yet licensed for pediatric PAH including tadalafil and vardenafil, among others. This article summarizes the evidence base for phosphodiesterase inhibitors used to ameliorate pediatric PAH pathology and associated symptoms. It also analyzes their suitability for contemporary practice with the aim of clarifying and helping to direct regimens that produce improved patient outcomes.

Original languageEnglish
Pages (from-to)213-9
Number of pages7
JournalPediatric Cardiology
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • Child
  • Heart Failure
  • Humans
  • Hypertension, Pulmonary
  • Phosphodiesterase Inhibitors
  • Pulmonary Wedge Pressure
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors'. Together they form a unique fingerprint.

  • Cite this